Trygve bridges discovery and translation, leading a team that decodes the regulatory programs defining brain cell identity and disease risk, with insights informing precision genetic tools for the next generation of brain therapies.

His team profiles and analyzes the human brain at single-cell resolution, drawing comparisons with model species to reveal what makes our brains distinct and what makes specific populations vulnerable to neurological disease. By pairing single-cell genomics with AI models that learn the regulatory grammar of DNA, his group is uncovering how cell type-specific gene expression is encoded in the genome. These advances enable the design of next-generation genetic tools and the prediction of how disease-associated variants disrupt regulation in at-risk cells, linking human cellular biology to disease mechanisms and therapeutic opportunity.

Trygve joined the Allen Institute in 2013 after earning his MD and PhD in Neurosciences at UC San Diego. He also holds an MSc from the London School of Economics and a BA from Yale University.  

‍